Revista Romana de PEDIATRIE | Volumul LXI, Nr. 3, An 2012
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398

Indexed in / abstracted by

Thomson Reuters Embase
Scopus Cross-ref
Index Copernicus
Ulrichs Ebsco Host
Medline - Ebsco PubMed


Publicarea de articole stiintifice

Stimati cititori, va reamintim ca autorii primi ai articolelor stiintifice pot acumula 80 de credite EMC in urma publicarii. Daca un articol are mai multi autori, cele 80 de credite [...]

Premiul Societatii pentru autori

Incepand cu 2016, Societatea Romana de Pediatrie ofera Premiul Societatii - pentru autorii celor mai bune articole stiintifice publicate [...]

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Pompe disease: criteria for diagnosis and treatment

, and


Pompe disease is a rare neuromuscular disorder, with autosomial recessive transmition due to deficiency of lysosomal enzymatic acid alpha glucosidase (GAA) with accumulation of glycogen in tissues. The infantileonset form is the most severe with hypotonia and cardiomyopathy with death in the first years of life. The diagnosis may be confirmed by analysis of GAA enzyme activity at fibroblasts level by muscle or skin biopsy. This method is realized by invasive procedures and results are obtained after few weeks thus delaying diagnosis. In the last few years assays on blood cells and dried blood spots have been developed, method that are not invasive and can help at early diagnostic of Pompe disease. Treatment is represented by enzyme replacement therapy with alglucosidase alfa. This treatment changes the natural course of the disease. In patients with infantile onset enzyme replacement therapy prolongs survival and in those with delay onset improve walking distance and stabilize pulmonary function.

Key words: Pompe disease, child, enzyme therapy

Full text | PDF

Leave a Reply